Cargando…

P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY

Detalles Bibliográficos
Autores principales:	Debaize, Lydie, Zhang, Ye, Ramseier, Michelle, Zhang, Mingzeng, Langenbucher, Adam, Winter, Peter S., Xu, Ran, Senhaji, Nezha, Redd, Robert A, Aryee, Martin J., Branch, Paul H., Kim, Austin I., Weinstock, David M., Shalek, Alex, Manalis, Scott R., Murakami, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431122/ http://dx.doi.org/10.1097/01.HS9.0000971724.96705.d3

Ejemplares similares

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
por: Liu, Zhuojun, et al.
Publicado: (2021)

Liu Sung-nien (1174–1224), Sung Dynasty. Lohan (1207)
por: Potter, Polyxeni
Publicado: (2004)

Nucleotide sequence of conjugative prophage Φ1207.3 (formerly Tn1207.3) carrying the mef(A)/msr(D) genes for eﬄux resistance to macrolides in Streptococcus pyogenes
por: Iannelli, Francesco, et al.
Publicado: (2014)

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
por: Pal, Dhananjaya, et al.
Publicado: (2021)

Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma
por: Vann, Kendra R., et al.
Publicado: (2022)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

1207. Epidemiology and Timing of Infectious Complications from Battlefield-Related Burn Injuries
por: Geringer, Matthew, et al.
Publicado: (2022)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia
por: Kunit, Thomas, et al.
Publicado: (2014)

miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer()
por: Das, Dibash K., et al.
Publicado: (2016)

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

1207. Vaccinia Virus Infection Acquired from an Occupational Needlestick—San Diego, California, 2019
por: Whitehouse, Erin R, et al.
Publicado: (2019)

Optimization of proximity ligation assay (PLA) for detection of protein interactions and fusion proteins in non-adherent cells: application to pre-B lymphocytes
por: Debaize, Lydie, et al.
Publicado: (2017)

High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays
por: Cermak, Nathan, et al.
Publicado: (2016)

Down-regulation of lncRNA LUADT1 suppresses cervical cancer cell growth by sequestering microRNA-1207-5p: LUADT1/miR-1207-5p/SEPT9 in cervical cancer
por: Zhang, Qian, et al.
Publicado: (2022)

Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
por: Hess, Lisa M., et al.
Publicado: (2022)

miR-1207-5p suppresses lung cancer growth and metastasis by targeting CSF1
por: Dang, Wei, et al.
Publicado: (2016)

IL23R and ATG16L1 variants in Moroccan patients with inflammatory bowel disease
por: Serbati, Nadia, et al.
Publicado: (2014)

The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
por: Senhaji, Nezha, et al.
Publicado: (2015)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Triplet‐triplet Annihilation Dynamics of Naphthalene
por: Gudem, Mahesh, et al.
Publicado: (2022)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

An Italian Neurorehabilitation Hospital Facing the SARS-CoV-2 Pandemic: Data From 1207 Patients and Workers
por: Salvia, Antonino, et al.
Publicado: (2020)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Triplets
por: Butts, Anna Louise
Publicado: (1930)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ia0fa32hs4gv0ea21sqh045ahi